Thursday, July 25, 2013

BMS announces Q2 2013 earnings results - Cuts EPS guidance for the year

Bristol-Myers Squibb announced its Q2-2013 earnings results. It has announced a cut in its annual earning guidance. BMS has adjusted its 2013 GAAP EPS guidance range to $1.41 to $1.49, from $1.54 to $1.64, and its non-GAAP EPS guidance range to $1.70 to $1.78, from $1.78 to $1.88. 

Among the new launches, Eliquis generated $12m during the quarter. Onglyza/Kombiglyze grew 40% year over year. Yeryoy grew 44 percent, generating $233m in quarterly sales.

Enter your email address:


Delivered by FeedBurner